Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review

A Correction to this article was published on 28 September 2021


Kratom is a legal, widely available substance that contains opioid agonist alkaloids. Due to the marketing of kratom as an opioid alternative for treatment of pain, anxiety, depression, or to reduce opioid withdrawal symptoms, the use of kratom has increased among persons in the USA including pregnant women. This systematic review of the peer-reviewed literature regarding kratom in relation to maternal and infant outcomes resulted in analysis of six case reports of prenatal kratom exposure. Maternal and infant withdrawal from kratom exposure was described in each case, resulting in pharmacologic treatment for both mothers and infants.


The opioid epidemic has brought attention to perinatal substance exposures and the resulting effects on pregnancy, maternal, and newborn outcomes. Besides the substances of use that are identified by routine history and toxicology, novel psychoactive substances (NPS) often are not routinely part of the health history obtained and remain undisclosed or undetected during pregnancy. NPS are legally sold on the internet and in retail locations such as gas stations, herbal stores, and “head shops” [1]. From 2000 to 2017, the United States poison control reported roughly 67,500 calls reporting exposure to NPS [2]. Kratom was one of the four leading substances that had the highest rates of hospitalization and serious medical outcomes. While most exposures to natural psychoactive substances have decreased over the years, exposures to kratom have increased drastically, by 4948.9%, from 2011 to 2017 [2].

cKratom, a derivative of Mitragyna speciosa, is in the coffee plant family and originated from Southeast Asia. Kratom is sold as tea, capsules, tablets, raw leaves, and concentrated extracts. The two main alkaloid substances found in kratom are mitragynine pseudoindoxyl and 7-hydroxymitragynine. Mitragynine is an opioid agonist with a small affinity for receptors. Conversely, 7-hydroxymitragynine has a much smaller presence in kratom, yet an increased potency as an opioid agonist [3, 4]. The alkaloid 7-hydroxymitragynine has been reported to have a higher potency than morphine [5]. A major challenge in understanding the actions and effects of kratom is the varying dosage of the alkaloids, additives, or alterations of kratom, the variability of dosage, and simultaneous polysubstance use by consumers [6, 7].

Metabolites of kratom will not appear on a standard urine toxicology. Standard analytical screening techniques for mitragynine and its metabolites, as with other NPS, require a more sophisticated liquid chromatography–mass spectrometry [8,9,10].

The primary reasons for use of kratom given by persons with past or present substance use disorder include pain, anxiety, depression, and to stop or reduce opioid use by reduction of withdrawal symptoms [11,12,13]. Kratom is popularly used and marketed in the USA as an opioid substitute and for the reduction of withdrawal symptoms [14,15,16,17,18]. In 2016, the Food and Drug Administration (FDA) attempted to list kratom as a Schedule 1 controlled substance [19], which generated a massive response from pro-kratom advocates. In 2018, the FDA released a report of 36 kratom-related overdose deaths with potential deadly interactions with other substances [20]. In the same year, the FDA released a warning of kratom contamination with multiple strains of Salmonella, which resulted in 199 people infected across 41 states and 38% of infected individuals were hospitalized [21]. A subset of states and cities in the USA has banned kratom (Alabama, Arkansas, Tennessee, San Diego, California, Indiana, Rhode Island, Vermont, Wisconsin). The debate on the benefits of kratom versus the risks continues, and highlights the need for research to inform clinical practice guidelines [22].

Prenatal use of kratom incidence is not fully known. The specific effects on pregnant women and their infants/children are unknown. The purpose of this systematic review was to analyze the current evidence published in peer-reviewed journals of the effects of kratom on human mothers and infants.


The peer-reviewed literature including prenatal kratom exposure and effects on mothers and newborns was analyzed using the following databases: PubMed, Cochrane Review, CINAHL, EBSCOhost, and Google Scholar. Search terms included kratom and pregnancy, kratom, kratom and neonatal effects, kratom and neonatal abstinence syndrome, kratom and infancy, kratom and newborn, and kratom and perinatal exposure. Inclusion criteria for the studies included: (1) the literature using English language; (2) peer-reviewed journals; (3) research studies; (4) studies of kratom when the use was during pregnancy; (5) studies that included effects on the mother and/or infant associated with use of kratom prenatally; and (6) case reports that included prenatal use of kratom and effects on the mother and/or infant. Exclusion criteria for the studies included: (1) non-English language literature; (2) journals that are not peer-reviewed; (3) the literature that was not research; (4) studies of kratom that did not include use during pregnancy; and (5) studies of kratom that did not include effects on the mother and/or the infant.

A total of 31 articles were found in the search of the databases using the search terms described (Fig. 1). Eighteen of the articles were duplicate and were excluded from the review. Abstracts of the remaining 13 articles were reviewed. Five of the articles did not pertain to infant or maternal outcomes relating to kratom prenatal exposure. The remaining eight articles were reviewed in full text. Three articles were excluded due to not being research or case reports in addition to not pertaining to infant or maternal outcomes related to prenatal kratom exposure. Five published case reports in peer-reviewed journals that pertained to prenatal kratom use and maternal/infant outcomes were included in the review (Fig. 1).

Fig. 1: Prisma flow diagram.
figure 1

Databases used: PubMed, CINAHL, Cochrane Review Google scholar, and EBSCOhost. Key search terms: “Kratom and neonatal abstinence syndrome,” “Kratom and neonatal effects,” and “Kratom and pregnancy”.


The review of the five case reports of prenatal kratom use and maternal and infant outcomes are summarized in Table 1. The five articles included six mothers with an age range of 39–37 years and used kratom during pregnancy [23,24,25,26,27]. The reasons mothers reported using kratom for included: (1) pain relief such as fibromyalgia, back pain, and restless leg syndrome; (2) anxiety; (3) relief of opioid withdrawal symptoms; and (4) desired opioid-like effects. Four of the six mothers used kratom 3–4 times per day for the entire pregnancy [23,24,25,26,27]. The cost of the kratom was reported by one mother as $40.00 per day [24]. Two mothers were treated with prescribed buprenorphine or buprenorphine and naloxone after weaning off kratom during pregnancy [27].

Table 1 Prenatal kratom exposure literature on maternal and infant outcomes.

Descriptions of the mothers’ withdrawal symptoms from kratom use were reported in the case studies and included anxiety, piloerection, diaphoresis, and restlessness. Symptoms of withdrawal were described as severe resulting in returning to kratom use or being treated with buprenorphine or buprenorphine and naloxone. One mother had to go to the emergency department due to the initial severity and presentation of her withdrawal symptoms when discontinuing kratom use [27]. Prior to pregnancy, one mother reported that if she missed a kratom dose for 4–6 h or if she tried to taper her kratom dose, she experienced symptoms that included diaphoresis, rhinorrhea, myalgia, anxiety, nausea, diarrhea, and piloerection [24]. Psychological dependence was also described by a mother as not being able to function at home or work without taking kratom [24].

Polysubstance use was reported in four cases and included prescribed substances for comorbid conditions [23, 25] (Table 1). Two cases had no other substances identified except kratom [24, 26].

The gestational age of five of the infants ranged between 37 weeks and 5 days to description of full term [23,24,25,26,27]. Infant outcomes included symptoms of neonatal abstinence syndrome in five out of six infants in the case reports, including the two infants that were only exposed to kratom prenatally. Symptoms of neonatal abstinence syndrome appeared to begin as early as 6–8 h after birth and could be detected up to 4 days after birth. The average length of stay in the hospital was ~10 days with a minimum stay of 3 days and a maximum stay of 12 days [23,24,25,26,27].

The five infants that exhibited withdrawal symptoms were pharmacologically treated with a morphine weaning protocol. One of the five was started on morphine then switched to clonidine after signs of over sedation. The infant developed sinus bradycardia on both morphine and clonidine and had no reported prenatal substance exposures other than kratom [26]. A Finnegan score of 18, prior to morphine treatment, was reported for the infant exposed to kratom (tea used 3–4 times per day), selective serotonin reuptake inhibitors, acetaminophen-methocarbamol, diphenhydramine, valacyclovir, ranitidine, loratadine, salbutamol, and citalopram [25]. One of the infants who was only exposed to kratom, with a maternal daily use pattern of kratom 18–20 g three times per day, developed abstinence symptoms day 2 postpartum. Symptoms included feeding intolerance, jitteriness, irritability, and emesis requiring IV morphine 10 mg/kg/h and was switched on day 7 to oral morphine when able to tolerate oral intake [24].

The one infant that did not exhibit neonatal withdrawal symptoms was not exposed to kratom at the end of pregnancy, but instead the mother was given 2 mg of buprenorphine to alleviate maternal symptoms of withdrawal [27]. In addition, this baby was discharged from the hospital when 3 days old without evidence of withdrawal symptoms and there was no without report in the case study of follow-up of the infant to monitor symptoms post discharge from the hospital.


The systematic review of the literature of prenatal kratom use and effects on maternal and infant outcomes revealed case reports of both maternal and infant withdrawal symptoms after kratom use in pregnancy. The majority of mothers in the case studies were using kratom daily prior to their pregnancy. All mothers reported consumption of kratom because of its opioid-like effects and 66.67% of mothers reported previously being dependent on opioids. Although the previous drug history of all mothers was unclear in the case studies, the women who attempted to decrease or stop their kratom usage reported symptoms similar to opioid withdrawal and expressed psychologic dependence on kratom. Women of childbearing age are using kratom and becoming pregnant without knowing or being advised of consequences of continued use during pregnancy.

Of the case reports that included toxicology results, the results were negative. The presence of kratom metabolites needs specific spectrometry [22] and the standard toxicology testing would be negative if not specifically ordered. Clinicians need to review toxicology panels and understand the limitations of routine testing to detect NPS such as kratom.

Polysubstance exposure was described in the case studies. One mother reported taking prescribed gabapentin during her pregnancy along with a variety of other drugs. Gabapentin while taking opioids has shown an increase in the opioid’s effects, and it is unknown whether kratom produces these same effects [28, 29]. The severity of the symptoms could not be fully analyzed due to inconsistent reporting of Finnegan scores in the case study reports; however, pharmacologic wean was needed whether or not the infants had polysubstance exposure or single exposure to kratom.

The treatment plan for the mothers was similar to typical opioid treatment plans. The various treatments performed to discontinue kratom usage included prenatal medically assisted therapy using buprenorphine or buprenorphine and naloxone, partial replacement of kratom with oral morphine (which both were completely weaned off after 4 weeks), and a rapid detoxification program with assistance of psychiatry and an addiction program. All of the treatment plans reported successfully weaning the women off kratom.

Infants experienced withdrawal symptoms that created a need for pharmacologic wean using morphine and in one case clonidine and morphine. In the only case report that did not require pharmacologic treatment, the mother was only using prescribed buprenorphine during the last months of pregnancy [27]. The infant was sent home 3 days after birth, which makes it possible that symptoms may have developed after discharge. Timing of infant withdrawal to prenatal kratom exposure is an area of research that is needed to guide timing of postbirth observation for withdrawal in infants.

Clinicians are educated to take a medical history that includes any drugs or other substances taken by a patient, especially during pregnancy. The public impression that herbal substances do not fall into the category of needing to be disclosed is based on the principal that these substances are “natural” and therefore do not need any special consideration. Due to marketing of kratom that claims it is a nonaddictive alternative for opioids without risk, mothers do not know the potential of risk if they use kratom [30]. In a qualitative study of pregnant or parenting mothers with substance use disorder, mothers expressed their concern on effects of substance use on their infant and were motived to discontinue use for the sake of their child(ren) [31]. Kratom use is not reported to child protective services because it is “legal.” All of these factors may lead to misinterpretation of the safety of prenatal exposure to kratom and other legal psychoactive substances. Clinicians providing services to childbearing age, pregnant, or parenting women should specifically ask about the use of any substance. It should be explained to mothers that any substance exposure for the growing fetus may have effects—some that are known and some that are just being discovered as different substances become more available. The lack of incidence data is a result of the current state of undiscoverable use of kratom in pregnancy. Adoption of a validated tool, such as the kratom dependence scale, may assist in screening for the increasing use of psychoactive substances [32]. Understanding the presence of exposure to psychoactive substances during pregnancy assists in anticipating the observation of withdrawal symptoms for both mother and infant in the postpartum period, and scheduling the appropriate timing of discharge to home. Offering substance use treatment, such as detoxification, counseling that includes motivational interviewing, trauma informed care, and medically assisted therapy, is a standard of practice to address substance use disorders and should be made available to all childbearing age and pregnant women.

Research is needed to study the potential impacts of prenatal kratom in maternal and infant outcomes. In order to study the effects of perinatal kratom use, foundational areas of research are needed that include: (1) patterns of maternal use during pregnancy; (2) reasons for use in pregnancy; (3) maternal symptomatology; and (4) reactions to self-weaning during pregnancy. Infant outcomes need to address the crossing of kratom through the placenta, the determination of toxicology identification of kratom exposure, the amount of kratom in breast milk transmission to infants, and the timing, severity, and signs of infant withdrawal from prenatal exposure. Kratom combined with other prescribed and nonprescribed substances is an area of research needed to determine if there is an increased severity of negative maternal and infant outcomes.


  1. Khey DN, Stogner JM, Miller BL. Emerging trends in drug use and distribution. New York, NY: Springer; 2014.

  2. O’Neill-Dee C, Spiller HA, Casavant MJ, Kistamgari S, Chounthirath T, Smith TA. Natural psychoactive substance-related exposures reported to United States poison control centers, 2000–2017. Clin Toxicol. 2019.

  3. National Center for Biotechnology Information. Mitragynine. PUBCHEM database. National Center for Biotechnology Information. 2021.

  4. Raffa RB, Pergolizzi JV, Taylor R, Ossipov MH. NEMA Research Group. Natur’s first “atypical opioid”: kratom and mitragynines. J Clin Pharmacol. 2018;43:437–41.

  5. Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull. 2004;52:916–28.

    CAS  Article  Google Scholar 

  6. Griffin OH III, Daniels JA, Gardner EA. Do you get what you paid for? An examination of products advertised as kratom. J Psychoactive Drugs. 2016;1–6.

  7. Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, Boyer EW. Suspected adulteration of commercial kratom products with 7-hydro-xymitragynine. J Med Toxicol. 2016:12:341–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Leg Med. 2016;130:127–38.

    Article  Google Scholar 

  9. Lee J, Park J, Go A, Moon H, Kim S, Jung S, et al. Urine multi-drug screening with GC-MS or LC–MS-MS using SALLE-hybrid PPT/SPE. J Anal Toxicol. 2018;42:617–24.

    CAS  Article  PubMed  Google Scholar 

  10. Sharma A, Kamble SH, Leon F, Chear HJY, King TL, Bethold EC, et al. Simultaneous quantification of ten key kratom alkaloids in Mitragyna speciose lef actrates and commercial products by untra-performance liquid chromatography-tandem mass spectrometry. Drug Test Anal. 2019;11:8.

    Article  Google Scholar 

  11. Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (Mitragyna speciose): user demographics, use patterns and implications for the opioid epidemic. Drug Alcohol Depend. 2020;208.

  12. Singh D, Chear JY, Narayanan S, Leon F, Sharma A, McCurdy R, et al. Patterns and reasons for kratom (Mitragyna speciose) use among current and former opioid poly-drug users. J Ethnopharmacol. 2020;249.

  13. Smith K, Lawson T. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 2017;180:340–8.

    Article  PubMed  Google Scholar 

  14. Boyer EW, Baby KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragyna speciose Korth). Addiction. 2008;103:2145–57.

    Article  Google Scholar 

  15. Grundmann O. Patterns of kratom use and health impact in the US—results from an online survey. Drug Alcohol Depend. 2017;176:63–70.

    Article  PubMed  Google Scholar 

  16. Smith KE, Lawson T. Prevalence and motivations of kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 2017;180:340–8.

    Article  PubMed  Google Scholar 

  17. Coe MA, Pilllitteri JL, Sembower MA, Gerlach KK, Henningfield JE. Kratom as a substitute for opioids: results from an online survey. Drug Alcohol Depend. 2019;202:24–32.

    CAS  Article  PubMed  Google Scholar 

  18. Saref A, Suraya S, Singh D, Grundmann O, Narayanan S, Swogger MT, et al. Self-reported prevalence and severity of opioid and kratom (Mitragyna speciose Korth) side effects. J Ethnopharmacol. 2019;238.

  19. US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse. US Food and Drug Administration. 2018.

  20. FDA. Statement from FDA Commissioner Scott Gottlieb, M.D., on new warning letters FDA is issuing to companies marketing kratom with unproven medical claims; and the agency’s ongoing concerns about kratom. FDA; 2018.

  21. U.S. Food and Drug Administration. FDA investigates multistate outbreak of salmonella infections linked to products reported to contain kratom. U.S. Food and Drug Administration. 2018.

  22. Prozioleck WC, Avery BA, Boyer EW, Grundmann O, Henningfield JE, Kruegel AC, et al. Kratom policy: the challenge of balancing therapeutic potential with public safety. Int J Drug Policy. 2019;70:70–7.

    Article  Google Scholar 

  23. Davidson L, Rawat M, Stojanovski S, Chandrasekharan P. Natural drugs, not so natural effects: neonatal abstinence syndrome secondary to ‘kratom’. J Neonatal-Perinat Med. 2019;12:109–12.

    CAS  Article  Google Scholar 

  24. Mackay L, Abrahams R. Novel case of maternal and neonatal kratom dependence and withdrawal. Can Fam Phys. 2018;64:121–2.

    Google Scholar 

  25. Murthy P, Clark D. An usual cause for neonatal abstinence syndrome. Pediatr Child Health. 2019;24:12–14.

    Article  Google Scholar 

  26. Eldridge WB, Foster C, Wyble L. Neonatal abstinence syndrome due to maternal kratom use. Pediatrics. 2018;142:e20181839.

    Article  PubMed  Google Scholar 

  27. Smid MC, Charles JE, Gordon AJ, Wright TE. Opioids case report use of kratom, an opioid-like traditional her, in pregnancy. Obstet Gynecol. 2018;132:926–8.

    Article  PubMed  Google Scholar 

  28. Loudin S, Murray S, Prunty L, Davies T, Evans J, Werthammer J. An atypical withdrawal syndrome in neonates prenatally exposed to gabapentin and opioids. J Pediatr. 2017;181:286–8.

    CAS  Article  Google Scholar 

  29. Bastiaens L, Galus J, Mazur C. Abuse of gabapentin is associated with opioid addiction. Psychiatr Q. 2016;87:763–7.

    Article  PubMed  Google Scholar 

  30. Farah T. Fears about kratom use during pregnancy are overblown. 2018.

  31. Wright ME, Temples HS. I do love my baby: stories of mothers with addiction and recovery. Columbia, SC: Amazon KDP publishing; 2019.

  32. Saingam D, Assanangkornchai S, Geater AF, Lerkiatbundit S. Validation of krathom (Mitragyna speciose Korth.) dependence scale (KDS): a dependence screen for internationally emerging psychoactive substance. Subst Abus. 2014;35:276–83.

    Article  PubMed  Google Scholar 

Download references


The project was partially supported by the Clemson Creative Inquiry Program.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Mary Ellen Wright.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: Madison Sherbondy has been added to the author list.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wright, M.E., Ginsberg, C., Parkison, A.M. et al. Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review. J Perinatol 41, 1236–1243 (2021).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links